Evidence map›Paper›PMID 40610417›Full record

ArticleNature communications2025

The mechanistic basis for interprotomer deglycosylation of antibodies by corynebacterial IgG-specific endoglycosidases.

Diego E Sastre, Stylianos Bournazos, Maros Huliciak, Barbara Ann C Grace, E Josephine Boder, Jonathan Du, Nazneen Sultana, Tala Azzam, Trenton J Brown, Maria W Flowers and 13 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Diego E SastreDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA. dsastre@emory.edu.ORCID http://orcid.org/0000-0003-2010-5398
Stylianos BournazosLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-5466-5620
Maros HuliciakDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-9929-3522
Barbara Ann C GraceLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.
E Josephine BoderLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.
Jonathan DuDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7750-4413
Nazneen SultanaDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Tala AzzamDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8739-7861
Trenton J BrownDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Maria W FlowersDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Pete LollarDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Ting XuDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Tatiana A ChernovaDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-1966-0159
Alasdair D KeithDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2569-5182
Meredith KeenDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Abigail SaltzmanDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Ana Martinez GascueñaStructural Glycoinmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
Beatriz TrastoyStructural Glycoinmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.ORCID http://orcid.org/0000-0002-2178-732X
Marcelo E GuerinStructural Glycobiology Laboratory, Department of Structural and Molecular Biology; Molecular Biology Institute of Barcelona (IBMB), CSIC, Barcelona Science Park, c/Baldiri Reixac 4-8, Tower R, Barcelona, Catalonia, Spain.ORCID http://orcid.org/0000-0001-9524-3184
Filipp FrankDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8680-2757
Eric A OrtlundDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8855-3029
Jeffrey V RavetchLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2024-9041
Eric J SundbergDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA. eric.sundberg@emory.edu.ORCID http://orcid.org/0000-0003-0478-3033

Funding

Technology Training and Dissemination CoreU54EB027690 · NIBIB · EMORY UNIVERSITY · PI Wilbur A Lam · 2018 to 2026
$96.1M
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$26.0M
Mechanisms of antibody-dependent enhancement of SARS-CoV-2 infectionR01AI137276 · NIAID · ROCKEFELLER UNIVERSITY · PI Stylianos Bournazos · 2018 to 2026
$4.5M
Rationalizing glycoengineering strategies for immunotherapeutic antibodiesR01AI149297 · NIAID · EMORY UNIVERSITY · PI JEFFREY Victor RAVETCH, ERIC JOHN SUNDBERG · 2020 to 2026
$3.7M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
Gatekeeping glycan metabolism in the human gut microbiomeR01GM148075 · NIGMS · EMORY UNIVERSITY · PI ERIC JOHN SUNDBERG · 2023 to 2026
$1.7M
NCI NIH HHS R01 CA244327NIAID NIH HHS R01 AI137276NIAID NIH HHS R01 AI149297NIAID NIH HHS U19 AI111825NIBIB NIH HHS U54 EB027690NIGMS NIH HHS R01 GM148075U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI149297
6 · The paper itself

Abstract

Corynebacterium diphtheriae clade species secrete single-domain endo-β-N-acetylglucosaminidases (ENGases) that specifically bind to human IgG antibodies and hydrolyze their N297-linked glycans. Here, we define the molecular mechanisms of IgG-specific deglycosylation for the entire family of corynebacterial IgG-specific ENGases, including but not limited to CU43 and CM49. By solving the crystal structure of CU43 in a 1:1 complex with the IgG1 Fc region, combined with targeted and saturation mutagenesis analysis and activity measurements using engineered antibodies, we establish an inter-protomeric mechanism of recognition and deglycosylation of IgG antibodies. Using in silico modeling, small-angle X-ray scattering and saturation mutagenesis we determine that CM49 uses a unique binding site on the Fc region, to process N297-linked glycans. Moreover, we demonstrate that CU43 treatment is highly effective in abrogating Fc effector functions in humanized mouse models, while preserving the neutralizing capacity of anti-influenza IgG antibodies, thereby conferring protection against lethal influenza challenge.

Indexed as

Bacterial ProteinsCorynebacteriumGlycoside HydrolasesImmunoglobulin GAnimalsBinding SitesCrystallography, X-RayGlycosylationHumansImmunoglobulin Fc FragmentsMiceModels, MolecularPolysaccharidesBacterial ProteinsGlycoside HydrolasesImmunoglobulin Fc FragmentsImmunoglobulin GPolysaccharides

Identifiers

PMID40610417
PMCPMC12229479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.